JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 163 filers reported holding JUNO THERAPEUTICS INC in Q4 2015. The put-call ratio across all filers is 2.35 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $482,140,000 | -0.9% | 10,547,788 | -2.8% | 0.60% | -2.8% |
| Q3 2017 | $486,659,000 | +45.7% | 10,848,400 | -2.9% | 0.62% | +37.2% |
| Q2 2017 | $333,964,000 | +34.4% | 11,173,129 | -0.2% | 0.45% | +24.0% |
| Q1 2017 | $248,481,000 | +19.2% | 11,197,863 | +1.2% | 0.36% | +5.5% |
| Q4 2016 | $208,518,000 | -36.0% | 11,061,955 | +2.0% | 0.34% | -32.6% |
| Q3 2016 | $325,574,000 | -21.9% | 10,848,851 | +0.0% | 0.51% | -31.6% |
| Q2 2016 | $416,831,000 | +0.2% | 10,843,672 | -0.7% | 0.74% | +1.6% |
| Q1 2016 | $415,880,000 | +3277.8% | 10,918,377 | +3799.4% | 0.73% | +3385.7% |
| Q4 2015 | $12,312,000 | – | 280,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |